Analyst Price Targets — SNN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 11, 2026 11:34 am | — | Bernstein | $31.85 | $29.95 | TheFly | Smith & Nephew price target lowered to $31.85 from $36.20 at Bernstein |
| May 11, 2026 11:09 am | — | Canaccord Genuity | $30.00 | $29.95 | TheFly | Smith & Nephew price target lowered to $30 from $32 at Canaccord |
| April 24, 2026 11:14 am | Caitlin Cronin | Canaccord Genuity | $32.00 | $31.92 | TheFly | Smith & Nephew price target lowered to $32 from $35 at Canaccord |
| October 14, 2025 10:53 am | — | Bernstein | $37.50 | $35.21 | TheFly | Smith & Nephew downgraded to Market Perform from Outperform at Bernstein |
| August 18, 2025 10:44 am | Caitlin Cronin | Canaccord Genuity | $36.00 | $36.54 | TheFly | Smith & Nephew price target raised to $36 from $28 at Canaccord |
| November 4, 2024 12:43 pm | Kyle Rose | Canaccord Genuity | $27.00 | $25.28 | StreetInsider | Smith & Nephew (SNN) PT Lowered to $27 at Canaccord Genuity |
Latest News for SNN
Panmure Liberum has cut its target price for Smith & Nephew PLC (LSE:SN), the medical devices maker, to 1120p from 1250p, while maintaining its 'hold' rating. The broker said it still struggled to make a credible investment case after a disappointing second quarter and the departure of chief financial officer John Rogers, who is leaving to become CFO of Baxter.
UBS has cut its price target on Smith & Nephew PLC (LSE:SN) to 1,120p from 1,300p, warning that even the medical device group's recently reduced guidance for this year remains at risk. The neutral rating is unchanged, with the new target implying about 3.5% upside from Monday's close of 1,082p.
BlackRock Inc. acquired a new stake in shares of Smith and Nephew SNATS, Inc. (NYSE: SNN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,056,801 shares of the medical equipment provider's stock, valued at approximately $505,323,000.
Smith+Nephew's five-year Imperial College London partnership targets less invasive robotic surgery and could speed research into clinical use.
Smith & Nephew PLC (LSE:SN) share prices weakened around 3% after the company announced that chief financial officer John Rogers will leave the company at the end of September. The medical technology group's shares fell as low as 3.5% in early London trading to around 1,072p against Tuesday's 1,110.5p close.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SNN.
Senate Trading
No Senate trades found for SNN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.